These are top 10 stocks traded on the Robinhood UK platform in July
On Wednesday, Cantor Fitzgerald analysts reiterated an Overweight rating for Centene stock (NYSE: NYSE:CNC) with a price target of $90.00. Their analysis indicates that Centene, along with other major payors, experienced fewer enrollment losses compared to the overall market. According to InvestingPro data, Centene, currently trading near its 52-week low at a P/E ratio of 8.2, appears undervalued based on its Fair Value analysis.
The analysis highlighted that HUMANA INC. (NYSE: HUM) saw the most significant difference, with only a 2% drop in enrollment compared to a 33% drop in the market. UNITEDHEALTH GROUP INC. (NYSE: UNH) reported 19% fewer losses, MOLINA HEALTHCARE, INC. (NYSE: MOH) 17%, CVS HEALTH CORPORATION (NYSE: CVS) 16%, CENTENE CORPORATION 12%, and ELEVANCE HEALTH, INC. (NYSE: ELV) 9%. With a market capitalization of $27.55B and revenue growth of 7.22%, Centene maintains its position as a prominent player in the healthcare sector.
These results suggest successful efforts in re-enrolling members, providing a positive outlook amid potential enrollment disruptions due to upcoming work requirements. The findings underscore the effectiveness of outreach programs in maintaining membership levels. InvestingPro analysis reveals the company maintains a "GREAT" overall financial health score, with 10+ additional exclusive insights available to subscribers.
The analysts’ report reflects confidence in Centene’s ability to navigate these challenges, reinforcing their positive stance on the company’s stock performance. For a deeper understanding of Centene’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Centene Corporation reported a strong performance in its first-quarter 2025 earnings, surpassing expectations with an adjusted diluted earnings per share (EPS) of $2.90, compared to the forecasted $2.38. The company’s revenue also exceeded forecasts, reaching $48.62 billion against a projected $42.79 billion. Despite these positive results, Barclays (LON:BARC) downgraded Centene’s stock from Overweight to Equalweight, citing concerns in the Part D and Affordable Care Act segments, and adjusted its 2025 and 2026 EPS estimates downward. Meanwhile, Cantor Fitzgerald maintained an Overweight rating on Centene, with a price target of $90, suggesting confidence in the company’s potential, especially in light of the proposed E&C Committee Budget Reconciliation Bill. Jefferies also adjusted its outlook on Centene, reducing the price target to $61 while maintaining a Hold rating, due to increased utilization pressure in various segments. Additionally, Centene’s annual shareholder meeting saw the approval of several key proposals, including the election of directors and the ratification of KPMG LLP as the independent accounting firm. However, two shareholder proposals related to climate change were not approved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.